| Literature DB >> 22249475 |
Sumeet S Mitter1, Reinaldo B Oriá, Michelle P Kvalsund, Paula Pamplona, Emanuella Silva Joventino, Rosa M S Mota, Davi C Gonçalves, Peter D Patrick, Richard L Guerrant, Aldo A M Lima.
Abstract
OBJECTIVE: Apolipoprotein E4 may benefit children during early periods of life when the body is challenged by infection and nutritional decline. We examined whether apolipoprotein E4 affects intestinal barrier function, improving short-term growth and long-term cognitive outcomes in Brazilian shantytown children.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22249475 PMCID: PMC3248595 DOI: 10.6061/clinics/2012(01)03
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Figure 1The gel electrophoresis banding patterns used to genotype amplified DNA of study subjects digested with the HhaI restriction enzyme were as follows: (Column 1) 50-basepair DNA ladder; (Column 4) APOE2,3 genotype; (Column 5) APOE3,3 genotype; (Column 6) APOE3,4 genotype; (Column 7) APOE4,4 genotype; (Column 8) 100-basepair DNA ladder.
Genotypic and allelic distribution of APOE in the analyzed population of the Parque Universitário community in Fortaleza, Ceará, Brazil.
| Genotype | Number | Frequency (%) |
| ε2ε2 | 0 | 0.00 |
| ε2ε3 | 10 | 6.94 |
| ε2ε4 | 1 | 0.69 |
| ε3ε3 | 97 | 67.36 |
| ε3ε4 | 33 | 22.92 |
| ε4ε4 | 3 | 2.06 |
| Total | 144 | 100 |
ε2 = APOE2, ε3 = APOE3, ε4 = APOE.
Demographic and anthropometric data for the Parque Universitário study population at baseline segregated by APOE4 allele status.
| Study Population | ||
| Characteristics | APOE4(+) | APOE4(-) |
| Sex | ||
| Female | 15 (40.5%) | 59 (55.1%) |
| Male | 22 (59.5%) | 48 (44.9%) |
| Birth weight (g) | 3100±484 (n = 36) | 3143±526 (n = 102) |
| Mean age at enrollment (m) | 51.13±30.30 (n = 37) | 55.47±26.32 (n = 107) |
| Mean age at cognitive testing (m) | 103.2±29.00 (n = 37) | 106.1±24.42 (n = 107) |
| Maternal education | ||
| Below primary school | 26 (70.3%) | 89 (83.2%) |
| Primary school or above | 9 (24.3%) | 18 (16.8%) |
| Unknown | 2 (5.4%) | — |
| Monthly income | ||
| <2 | 25 (67.6%) | 64 (59.8%) |
| ≥2 | 2 (5.4%) | 15 (14.0%) |
| Unknown | 10 (27.0%) | 28 (26.2%) |
| Household crowding (≥3 persons/room) | ||
| No | 18 (48.6%) | 45 (42.1%) |
| Yes | 19 (51.4%) | 61 (57.0%) |
| Unknown | — | 1 (0.9%) |
| HAZ | ||
| No | 20 (54.1%) | 60 (56.1%) |
| Yes | 17 (45.9%) | 47 (43.9%) |
| WAZ | ||
| No | 22 (59.5%) | 61 (57.0%) |
| Yes | 15 (40.5%) | 46 (43.0%) |
| WHZ | ||
| No | 31 (83.8%) | 85 (79.4%) |
| Yes | 6 (16.2%) | 22 (20.6%) |
| L/M | ||
| No | 18 (62.1%) | 55 (59.1%) |
| Yes | 11 (37.9%) | 38 (40.9%) |
1 minimum wage: US $102/month.
HAZ, WAZ, WHZ, L/M at study enrollment.
Pearson correlations between the change in the lactulose:mannitol (L/M) ratio (an intestinal permeability indicator) during the initial 4 months of nutritional supplementation and ΔHAZ*) (t4-t0), ΔWAZ*) (t4-t0) and ΔWHZ*) (t4-t0) according to the experimental nutrition groups.
| ΔL/M(t4-t0) | |||||||||||||||||||||
| Gln | Zn | Vit. A | Vit. A+Zn | Zn+Gln | Vit. A+Gln | Vit. A+Zn+Gln | |||||||||||||||
| N | N | N | N | N | N | N | |||||||||||||||
| ΔHAZ | 16 | -0.005 | 0.986 | 11 | -0.509 | 0.110 | 8 | 0.326 | 0.431 | 12 | -0.333 | 0.291 | 13 | 0.305 | 0.310 | 15 | 0.061 | 0.829 | 9 | 0.013 | 0.974 |
| ΔWAZ | 16 | 0.277 | 0.299 | 11 | 0.071 | 0.836 | 8 | 0.494 | 0.213 | 12 | -0.512 | 0.088 | 13 | -0.411 | 0.164 | 15 | -0.593 | 9 | 0.489 | 0.182 | |
| ΔWHZ | 16 | 0.251 | 0.348 | 11 | 0.429 | 0.188 | 8 | 0.247 | 0.555 | 12 | -0.383 | 0.219 | 13 | -0.404 | 0.171 | 15 | -0.554 | 9 | 0.268 | 0.485 | |
HAZ = height-for-age z-scores, WAZ = weight-for-age z-scores, WHZ = weight-for-height z-scores.
Gln = glutamine; Zn = zinc; Vit. A = vitamin A.
Pearson correlations between the change in the lactulose:mannitol (L/M) ratio (an intestinal permeability indicator) during the initial 4 months of nutritional supplementation and ΔHAZ*) (t4-t0), ΔWAZ*) (t4-t0) and ΔWHZ*) (t4-t0) according to APOE4 genotyping.
| ΔL/M(t4-t0) | |||||||
| APOE4(+) | APOE4(-) | ||||||
| N | N | ||||||
| Glutamine | ▵HAZ | 16 | 0.137 | 0.613 | 37 | 0.122 | 0.470 |
| ▵WAZ | 16 | -0.132 | 0.625 | 37 | -0.036 | 0.834 | |
| ▵WHZ | 16 | -0.134 | 0.622 | 37 | -0.096 | 0.572 | |
| Zinc | ▵HAZ | 8 | 0.165 | 0.697 | 37 | 0.001 | 0.995 |
| ▵WAZ | 8 | -0.583 | 0.130 | 37 | -0.105 | 0.534 | |
| ▵WHZ | 8 | -0.460 | 0.251 | 37 | -0.115 | 0.500 | |
| Vitamin A | ▵HAZ | 10 | -0.014 | 0.970 | 34 | -0.101 | 0.569 |
| ▵WAZ | 10 | -0.654 | 34 | 0.260 | 0.137 | ||
| ▵WHZ | 10 | -0.470 | 0.171 | 34 | 0.263 | 0.132 | |
HAZ = height-for-age z-scores, WAZ = weight-for-age z-scores, WHZ = weight-for-height z-scores.
APOE4(+) = children carrying genotypes 3/4; 2/4; 4/4.
APOE4(-) = children carrying genotypes 2/2; 3/2; 3/3.
Figure 2Scatter plots indicating significant positive Pearson correlations between the changes in anthropometric indicators over 4 months and cognitive testing in the APOE4(+) population receiving glutamine supplementation: (A) ΔHAZ* (t4-t0) vs. WRAML-delayed verbal learning (n = 21); (B) ΔWAZ* (t4-t0) vs. TONI-3-IQ (n = 21); and (C) ΔWHZ* (t4-t0) vs. TONI-3-IQ (n = 21). *HAZ = height-for-age z-scores, WAZ = weight-for-age z-scores, WHZ = weight-for-height z-scores.
Pearson correlations between the change in the lactulose:mannitol (L/M) ratio (an intestinal permeability indicator) during the initial 4 months of nutritional supplementation and the battery of cognitive tests used to study shantytown children segregated by micronutrient supplementation and APOE4 allele carriage.
| ΔL/M(t4-t0) | |||||||
| APOE4(+) | APOE4(-) | ||||||
| N | N | ||||||
| Glutamine | WRAML-verbal learning | 16 | 0.400 | 0.125 | 37 | -0.295 | 0.076 |
| WRAML-delayed verbal learning | 16 | 0.122 | 0.652 | 37 | 0.011 | 0.950 | |
| TONI-3-IQ | 16 | 0.218 | 0.417 | 37 | -0.305 | 0.066 | |
| WISC-III-coding | 16 | 0.281 | 0.292 | 37 | 0.071 | 0.675 | |
| NEPSY-verbal fluency | 16 | -0.093 | 0.731 | 34 | 0.038 | 0.833 | |
| Zinc | WRAML-verbal learning | 8 | 0.349 | 0.396 | 37 | -0.431 | |
| WRAML-delayed verbal learning | 8 | 0.372 | 0.364 | 37 | -0.221 | 0.188 | |
| TONI-3-IQ | 8 | 0.189 | 0.655 | 37 | -0.428 | ||
| WISC-III-coding | 8 | 0.222 | 0.598 | 37 | -0.083 | 0.626 | |
| NEPSY-verbal fluency | 8 | 0.163 | 0.701 | 35 | -0.207 | 0.234 | |
| Vitamin A | WRAML-verbal learning | 10 | 0.170 | 0.768 | 34 | -0.425 | |
| WRAML-delayed verbal learning | 10 | -0.212 | 0.556 | 34 | -0.385 | ||
| TONI-3-IQ | 10 | -0.510 | 0.132 | 34 | -0.332 | 0.055 | |
| WISC-III-coding | 10 | 0.090 | 0.805 | 34 | -0.148 | 0.405 | |
| NEPSY-verbal fluency | 10 | -0.511 | 0.131 | 33 | -0.258 | 0.148 | |
Note: The subgroups for the statistical analysis were clustered based on pooled data for all children receiving glutamine, all children receiving zinc and all children receiving vitamin A to increase the number of individuals in each subgroup and enhance the power of the analysis.
APOE4(+) = children carrying genotypes 3/4; 2/4; 4/4.
APOE4(-) = children carrying genotypes 2/2; 3/2; 3/3.